Click image to open full size
The Drug Discovery Pipeline
From Target to FDA Approval
Related Tools
Related Labs
Related Worksheets
Drug discovery is the long process of turning a biological idea into a medicine that doctors can prescribe. It matters because every approved drug must show that it can help patients while keeping risks as low as possible. Researchers begin with thousands of possible molecules, but most fail because they are unsafe, ineffective, unstable, or too hard to manufacture. The full pipeline often takes 10 to 15 years and can cost about 2.6 billion USD per approved drug.
The process starts with target identification, where scientists choose a molecule, pathway, or cell process linked to a disease. Candidate drugs are then screened, optimized, and tested in cells and animals before any human study begins. Human clinical trials move through Phase 1 safety testing, Phase 2 efficacy testing, and Phase 3 large scale confirmation before regulatory review. After approval, Phase 4 post-market surveillance continues to track safety and effectiveness in the wider population.
Key Facts
- Typical timeline from discovery to approval: about 10 to 15 years.
- Success rate: about 1 in 5000 drug candidates reaches the market.
- Estimated cost per approved drug: about 2.6 billion USD.
- Phase 1 tests safety, dosage, and side effects in a small group of people.
- Phase 2 tests whether the drug works for the target disease and continues safety monitoring.
- Phase 3 tests effectiveness and rare side effects in large patient populations before FDA approval.
Vocabulary
- Target identification
- Target identification is the process of finding a biological molecule or pathway that can be changed to treat a disease.
- Lead compound
- A lead compound is a promising molecule that has useful activity against a target and can be improved through chemical modification.
- Preclinical testing
- Preclinical testing uses cells, tissues, and animal models to study a drug candidate before it is tested in humans.
- Clinical trial
- A clinical trial is a carefully designed study that tests a medical treatment in human volunteers or patients.
- Post-market surveillance
- Post-market surveillance is the ongoing monitoring of an approved drug after it is used by the general public.
Common Mistakes to Avoid
- Assuming a drug that works in cells will work in patients. Cell models are simplified systems and cannot fully reproduce human metabolism, immunity, or disease complexity.
- Confusing Phase 1 with proof that a drug cures disease. Phase 1 mainly evaluates safety, dose range, and side effects, often before strong evidence of benefit exists.
- Ignoring the high failure rate between discovery and approval. Most candidates fail because of toxicity, weak efficacy, poor absorption, or manufacturing problems.
- Treating FDA approval as the end of research. Phase 4 monitoring is still needed because rare side effects may appear only after many more people use the drug.
Practice Questions
- 1 If 5000 drug candidates enter early discovery and about 1 reaches the market, what percentage of candidates are approved?
- 2 A drug program takes 14 years and costs 2.6 billion USD. What is the average cost per year in millions of USD?
- 3 A candidate drug performs well in animal models but fails in Phase 2 trials. Explain two scientific reasons why this can happen.